Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$100.76

0.01 (0.01%)

07:25
04/14/18
04/14
07:25
04/14/18
07:25

Alnylam to hold a conference call

Management discusses the new results from the Phase 1 and Phase 1/2 open-label extension (OLE) studies of Givosiran on a conference call to be held on April 14 at 8 am. Webcast Link

  • 14

    Apr

  • 20

    Apr

  • 08

    May

  • 30

    May

  • 11

    Aug

ALNY Alnylam
$100.76

0.01 (0.01%)

04/03/18
JMPS
04/03/18
NO CHANGE
Target $207
JMPS
Outperform
JMP Securities says Alnylam selloff an 'extreme overreaction' to competitor data
After speaking to Alnylam (ALNY) management about competitor Pfizer's (PFE) positive top-line trial results for tafamidis in patients with transthyretin cardiomyopathy, JMP Securities analyst Michael King said Alnylam believes patisiran has a superior competitive profile compared to tafamidis in patients with hATTR-FAP. He views the selloff in Alnylam shares as "an extreme overreaction" to the presence of a competitor, reminding investors of recent International Symposium on Amyloidosis data that he said suggest that ALN-TTRsc02 will be well positioned with respect to tafamidis. King reiterates his Outperform rating and $207 price target on Alnylam.
04/02/18
JEFF
04/02/18
NO CHANGE
JEFF
Buy
Alnylam weakness on Pfizer data a buying opportunity, says Jefferies
Jefferies analyst Maury Raycroft noted that Alnylam (ALNY) fell by over 8% on Thursday after Pfizer (PFE) announced that the phase 3 ATTR-ACT trial assessing tafamidis in TTR-CM met its primary endpoint and that Alnylam shares are trailing the iShares Nasdaq Biotechnology Index (IBB) again today. While he thinks the tafamidis data provide important clinical outcome results that support the need for treatment and benefit in TTR-CM, he also continues to believe the benefits of knocking down/depleting TTR in earlier-stage patients, as Alnylam's patisiran is meant to do, will lead to better objective improvements, Raycroft tells investors. The analyst, who recommends investors buy Alnylam amid the weakness, keeps a Buy rating on the stock.
03/29/18
PIPR
03/29/18
NO CHANGE
Target $182
PIPR
Overweight
Piper says Pfizer's tafamidis poses minimal threat to Alnylam's patisiran
Piper Jaffray analyst Edward Tenthoff attributes weakness in shares of Alnylam (ALNY) to Pfizer (PFE) having reported that tafamidis achieved a significant reduction in all-cause mortality and frequency of cardiovascular-related hospitalizations vs. placebo at 30 months in a trial of ATTR cardiomyopathy patients. However, he would be a buyer of Alnylam amid the pullback, as he sees a minimal competitive threat, contending that patisiran's mechanism of mRNA knockdown is more potent than tafamidis' stabilization. The analyst, who expects patisiran to receive FDA approval broadly in ATTR amyloidosis polyneuropathy and cardiomyopathy by its PDUFA date of August 11, maintains an Overweight rating and $182 price target on Alnylam.
03/28/18
EVER
03/28/18
INITIATION
Target $143
EVER
In Line
Alnylam initiated with an In Line at Evercore ISI
Evercore ISI started Alnylam Pharmaceuticals with an In Line rating and $143 price target.

TODAY'S FREE FLY STORIES

TSLA

Tesla

$293.42

5.8 (2.02%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
Tesla batteries delivering power at 662 locations in Puerto Rico, Musk says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$109.31

-0.9 (-0.82%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
JPMorgan Chase announces branch expansion in Greater Washington DC »

JPMorgan Chase announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

ICLK

iClick Interactive Asia

$7.76

0.19 (2.51%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Conference/Events
iClick Interactive Asia management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 20

    Apr

SBNY

Signature Bank

$135.08

-1.99 (-1.45%)

05:52
04/19/18
04/19
05:52
04/19/18
05:52
Hot Stocks
Signature Bank reports Q1 EPS ex-items $2.69, consensus $2.67 »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

SCCO

Southern Copper

$57.33

0.745 (1.32%)

05:50
04/19/18
04/19
05:50
04/19/18
05:50
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

, DIS

Disney

$101.21

-1 (-0.98%)

05:49
04/19/18
04/19
05:49
04/19/18
05:49
Hot Stocks
21st Century Fox rejected rival bid of $34.41 per share for assets »

Disney (DIS) disclosed…

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

DIS

Disney

$101.21

-1 (-0.98%)

CMCSA

Comcast

$33.28

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 09

    May

NTRS

Northern Trust

$106.38

-0.04 (-0.04%)

05:47
04/19/18
04/19
05:47
04/19/18
05:47
Hot Stocks
Northern Trust enters partnership with The Northern Pool »

The Northern Pool has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$81.72

-0.09 (-0.11%)

, AMGN

Amgen

$175.14

0.19 (0.11%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Hot Stocks
Novartis appoints John Tsai as Chief Medical Officer, Head of GDD »

Novartis (NVS) announced…

NVS

Novartis

$81.72

-0.09 (-0.11%)

AMGN

Amgen

$175.14

0.19 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 05

    Jun

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Recommendations
Amazon.com analyst commentary  »

Amazon online retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Earnings
Novartis confirms FY18 revenue guidance of growth of low to mid single-digit »

Novartis noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Hot Stocks
Novartis reports Q1 Alcon sales of $1.8B »

Alcon net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

RDN

Radian Group

$15.36

-0.91 (-5.59%)

05:30
04/19/18
04/19
05:30
04/19/18
05:30
Recommendations
Radian Group analyst commentary  »

Radian Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Hot Stocks
Novartis Q1 results continue to demonstrate benefit from turnaround plan actions »

Novartis noted, Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Downgrade
MGIC Investment rating change  »

MGIC Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

, MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:28
04/19/18
04/19
05:28
04/19/18
05:28
Downgrade
Essent Group, MGIC Investment, Radian Group rating change  »

Essent Group downgraded…

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

RDN

Radian Group

$15.36

-0.91 (-5.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:27
04/19/18
04/19
05:27
04/19/18
05:27
Hot Stocks
Novartis reports Q1 Sandoz net sales of $2.5B »

Sandoz net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:25
04/19/18
04/19
05:25
04/19/18
05:25
Earnings
Novartis reports Q1 core EPS $1.28, consensus $1.29 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

, TEVA

Teva

$17.91

0.065 (0.36%)

05:23
04/19/18
04/19
05:23
04/19/18
05:23
Hot Stocks
Procter & Gamble acquires Consumer Health business of Merck KGaA for EUR 3.4B »

Procter & Gamble (PG)…

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

TEVA

Teva

$17.91

0.065 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

  • 18

    May

  • 05

    Jun

  • 16

    Jun

GOL

GOL Linhas

$13.51

0.72 (5.63%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Downgrade
GOL Linhas rating change  »

GOL Linhas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Hot Stocks
Breaking Hot Stocks news story on Procter & Gamble »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

LN

Line Corp.

$38.30

0.09 (0.24%)

05:20
04/19/18
04/19
05:20
04/19/18
05:20
Downgrade
Line Corp. rating change  »

Line Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.84

-0.41 (-0.23%)

05:16
04/19/18
04/19
05:16
04/19/18
05:16
Recommendations
Apple analyst commentary  »

Mizuho sees risk to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

SNBR

Sleep Number

$36.58

-0.35 (-0.95%)

05:13
04/19/18
04/19
05:13
04/19/18
05:13
Downgrade
Sleep Number rating change  »

Sleep Number downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOV

National Oilwell

$38.32

0.73 (1.94%)

05:12
04/19/18
04/19
05:12
04/19/18
05:12
Downgrade
National Oilwell rating change  »

National Oilwell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 22

    May

PTEN

Patterson-UTI

$20.61

0.41 (2.03%)

05:12
04/19/18
04/19
05:12
04/19/18
05:12
Downgrade
Patterson-UTI rating change  »

Patterson-UTI downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 22

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.